Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$1.00
-$0.03(-0.72%)
At close: 4:00 PM EST
$1.00
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.55 - $2.22
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$9.46M
Enterprise Value-$40.67M
Total Cash (Recent Filing)$46.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding12,382,776
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-4.30
Enterprise Value/Revenue-344.33
Enterprise Value/Gross Profit22.60
Enterprise Value/Ebitda3.24
Forecast
1Y Price Target
$4.07Price Target Upside306.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayHaving $46.5M and a projected runway into Q1 2028 materially lowers near-term financing urgency, giving management time to advance APR-1051 through dose escalation and ASCO 2026. This durable buffer reduces refinancing risk and enables execution toward clinical inflection points before new funding is needed.
Early APR-1051 Clinical SignalsObserved partial responses and generally favorable tolerability in biomarker-selected patients provide early proof-of-concept for APR-1051. Durable clinical signals can expand target indications, justify larger trials, and attract partners or non-dilutive funding, materially improving long-term commercial and development prospects.
Low Leverage / No DebtEffectively zero debt reduces interest-rate and refinancing exposure, giving the company financial flexibility. For a development-stage biotech this structural strength preserves optionality to pursue partnerships, licensing or staged financings without immediate interest-service pressure, improving strategic choices.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$12.2M TTM) means the business depends on periodic financing to fund R&D and trials. Even with current runway, ongoing burn creates dilution risk and constrains long-term program sequencing if trial timelines or enrollment extend beyond forecasted cash availability.
Ongoing Losses And Weak RevenueConsistent net losses and volatile, declining revenue reflect a pre-commercial model with no recurring cash flows. This structural lack of revenue limits self-funding, increases reliance on capital markets or partners, and makes long-term margin recovery contingent on successful clinical-to-commercial transitions.
Program Execution Uncertainty (ATRN-119 Pause)Pausing ATRN-119 monotherapy enrollment increases timeline and execution risk for that program. Pivoting to combination strategies adds scientific and regulatory complexity, likely requiring additional studies and partnerships, which can stretch resources and delay or dilute near-term value realization.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $2.22 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $9.46M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.008.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,382,776 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$4.07
▲(306.67% Upside)
Technical Analysis
Ownership Overview
6.30% Insiders
0.86% Mutual Funds
15.36% Other Institutional Investors
77.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---